VOXVOGANAN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C43H69N11O3
Molecular Weight	788.0799
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)C1=C(C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCCC2=CC=CC=C2)C3=C(N1)C(=CC(=C3)C(C)(C)C)C(C)(C)C

InChI

InChIKey=ZVOYWSKEBVVLGW-ZDCRTTOTSA-N

InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C43H69N11O3
Molecular Weight	788.0799
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21732630 | https://www.ncbi.nlm.nih.gov/pubmed/23874964 | https://adisinsight.springer.com/drugs/800032182

LTX109 is a synthetic antimicrobial agent and is a potent fungicide that disturbs plasma membrane integrity in a sphingolipid dependent manner. LTX109 was in clinical phase II trials for topical treatment of infections of multiresistant bacterial strains. However, the further development of this drug apparently has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Postantibiotic effect and postantibiotic sub-MIC effect of LTX-109 and mupirocin on Staphylococcus aureus blood isolates.	2017-11	28802058
Mimics of Host Defense Proteins; Strategies for Translation to Therapeutic Applications.	2017	27411325
In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus.	2012-08	22585222
A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption.	2011-08-25	21732630

Sample Use Guides

In Vivo Use Guide

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA). Ascending dose study. Start enrollment to group 1: 1% LTX-109/placebo, then group 2: 2% LTX-109/placebo and finally group 3: 5% LTX-109/placebo dosed in each nostril TID for 3 consecutive days.

Route of Administration: Topical

In Vitro Use Guide

LTX-109 demonstrated a MIC range of 2 to 4 μg/ml and dose-dependent rapid bactericidal activity against S. aureus.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:56:22 GMT 2025` Edited by `admin` on `Mon Mar 31 17:56:22 GMT 2025`
Record UNII	HO813QDF65
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VOXVOGANAN

Official Name

English

LTX-109

Preferred Name

English

voxvoganan [INN]

Common Name

English

L-ARGININAMIDE, L-ARGINYL-2,5,7-TRIS(1,1-DIMETHYLETHYL)-L-TRYPTOPHYL-N-(2-PHENYLETHYL)-

Common Name

English

LTX 109 [WHO-DD]

Common Name

English

LTX109

Code

English

Code System Code Type Description

FDA UNII

HO813QDF65